Straits Times Index
3,270.98 -11.90 (-0.36%) Nikkei
27,999.96 -249.28 (-0.88%) Hang Seng
20,003.44 -42.33 (-0.21%) FTSE 100
7,490.06 +7.69 (+0.10%) BTC-USD
23,305.07 -792.87 (-3.29%) CMC Crypto 200
541.39 -15.96 (-2.86%)
VRTX Jan 2023 165.000 call
| Previous close | 70.80 |
| Open | 71.20 |
| Bid | 91.60 |
| Ask | 100.50 |
| Strike | 165.00 |
| Expiry date | 2023-01-20 |
| Day's range | 70.80 - 71.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
- Motley Fool
2 Top Biotech Stocks Defying the Bear Market
Vertex Pharmaceuticals' shares have soared 24% year to date despite the macroeconomic headwinds in its way. The biotech owes that in part to its dominance in the market for drugs that treat the underlying causes of cystic fibrosis (CF), an area in which Vertex is the only game in town. Revenue and earnings continue to grow for Vertex thanks to its CF franchise.
- Motley Fool
Why Vertex Pharmaceuticals Stock Was Soaring Today
An estimates-beating quarter and raised guidance were the elements pushing Vertex Pharmaceuticals (NASDAQ: VRTX) shares comfortably higher on Friday. After market hours on Thursday, Vertex published its second-quarter results. Vertex's growth was powered by its current blockbuster drug, Trikafta.
- Motley Fool
Vertex Pharmaceuticals (VRTX) Q2 2022 Earnings Call Transcript
Image source: The Motley Fool. Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2022 Earnings CallAug 04, 2022, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the Vertex Pharmaceuticals second quarter 2022 earnings call.
